SAB Biotherapeutics, Inc.
SABS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$2.79
KIRA · Stoqly’s AI analyst, in plain words
- SAB Biotherapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- SAB Biotherapeutics, Inc. made $13.3M of net profit in fiscal 2025.
- Free cash flow was −$45.7M in fiscal 2025, — of revenue.
Market cap
$223M
P/E
12.1x
Revenue
$0.0M
Net income
$13.3M
Free cash flow
−$45.7M
Operating margin
—
SAB Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
$13.3M
Yes. It made $13.3M of profit last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
12.1x
One share costs 12.1 times its yearly profit per share.
What SAB Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- SAB Biotherapeutics, Inc.
- CIK
- 0001833214
SAB Biotherapeutics, Inc. · SABS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $60.9M | $23.9M | $2.2M | $1.3M | $0.0M |
| Revenue growth | 10.2% | −60.7% | −90.6% | −40.9% | −100.0% |
| Operating margin | −22.0% | −121.0% | −1,700.5% | −3,244.9% | — |
| Net income | −$17.1M | −$18.7M | −$42.2M | −$34.1M | $13.3M |
| Net margin | −28.2% | −78.4% | −1,884.5% | −2,579.0% | — |
| Diluted EPS | −$0.63 | −$4.31 | −$7.64 | −$3.68 | −$0.79 |
| Cash | |||||
| Cash from operations | $2.0M | −$23.5M | −$25.1M | −$34.3M | −$44.8M |
| Capital expenditure | $10.9M | $2.2M | $0.2M | $0.3M | $0.9M |
| Free cash flow | −$9.0M | −$25.6M | −$25.3M | −$34.6M | −$45.7M |
| FCF margin | −14.7% | −107.2% | −1,130.7% | −2,618.7% | — |
| Share count change | 1.2% | −84.1% | 26.9% | 67.7% | 562.3% |
| Debt and strength | |||||
| Cash and short-term investments | $33.2M | $15.0M | $56.6M | $20.8M | $96.6M |
| Shareholders' equity | $38.5M | $31.1M | $57.3M | $26.0M | $151M |
| Current ratio | 1.9x | 1.5x | 5.4x | 3.0x | 9.5x |
| Interest coverage | −45.5x | −95.9x | −120.8x | −134.8x | −203.4x |
| Returns and quality | |||||
| Return on equity | −44.2% | −53.8% | −95.5% | −81.9% | 15.0% |
| Return on tangible equity | −44.5% | −60.3% | −73.6% | −131.3% | 2.8% |
| Piotroski F-score | 2 | 1 | 2 | 1 | 3 |
| Altman Z'' | 0.6 | −4.3 | −0.5 | −11.8 | 6.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
SAB Biotherapeutics, Inc. · SABS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.79 a share, the company is worth $223M: 12.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001833214). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.